Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: Potential implications for dosing in clinical practice

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 5, 2015, Pages 529-539

  Buurman, D J ^a   Maurer, J M ^a   Keizer, R J ^b   Kosterink, J G W ^a,c   Dijkstra, G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; DRUG ANTIBODY; INFLIXIMAB; GASTROINTESTINAL AGENT; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INTENSIFICATION; DRUG DOSE REGIMEN; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT DURATION; ULCERATIVE COLITIS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; MONTE CARLO METHOD; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; MALE; MIDDLE AGED; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84938555154     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13299     Document Type: Article

References (36)

1. Van Assche G, Dignass A, Reinisch W, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 2010; 4: 63-101.
2. Stange EF, Travis SP, Vermeire S, et al,. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
5. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
6. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A,. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut 2012; 61: 321; author reply 322.
7. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
8. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
9. Levesque BG, Greenberg GR, Zou G, et al,. A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease. Aliment Pharmacol Ther 2014; 39: 1126-35.
10. Maser EA, Villela R, Silverberg MS, Greenberg GR,. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54.
11. Nanda KS, Cheifetz AS, Moss AC,. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol 2013; 108: 40-7; quiz 48.
12. Cornillie F, Hanauer S, Diamond R, et al,. Postinductionserum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721-7.
13. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM,. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010; 48: 297-308.
14. Reinisch W, Wang Y, Oddens BJ, Link R,. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568-76.
15. Vande Casteele N, Khanna R, Levesque BG, et al,. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut. 2014 Oct 21. [Epub ahead of print].
16. Paul S, Del Tedesco E, Marotte H, et al,. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568-76.
17. Bortlik M, Duricova D, Malickova K, et al,. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013; 7: 736-43.
18. Imaeda H, Bamba S, Takahashi K, et al,. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol 2014; 49: 674-82.
19. van de Casteele N,. 1159 results on the optimisation phase of the prospective controlled trough level adapted infliximab treatment (TAXIT) Trial. Gastroenterology 2012; 5: 211-2.
20. van der Valk ME, Mangen MJ, Leenders M, et al,. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014; 63: 72-9.
21. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al,. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523-9.
22. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33: 946-64.
23. Fasanmade AA, Adedokun OJ, Ford J, et al,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-28.
24. Harvey RF, Bradshaw JM,. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514.
25. Jamnitski A, Bartelds GM, Nurmohamed MT, et al,. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011; 70: 284-8.
26. van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP,. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010; 69: 624-5.
27. Vande Casteele N, Buurman DJ, Sturkenboom MG, et al,. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012; 36: 765-71.
28. Xu Z, Seitz K, Fasanmade A, et al,. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-95.
29. Keizer RJ, Karlsson MO, Hooker A,. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: e50.
30. Schnitzler F, Fidder H, Ferrante M, et al,. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
31. Regueiro M, Siemanowski B, Kip KE, Plevy S,. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9.
32. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
33. Katz L, Gisbert JP, Manoogian B, et al,. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012; 11: 2020-33.
34. Kopylov U, Mantzaris GJ, Katsanos KH, et al,. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011 Feb; 33: 349-57.
35. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 493-507.
36. Vande Casteele N, Gils A, Singh S, et al,. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71.